ArticleJACC. Case reports2025
PET MPI With F-18 FlurpiridazVersus Rb-82: Insights Into Blood Flow and Splenic Switch-Off.
Article in JACC. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundF-18 flurpiridaz is a new, Food & Drug Administration-approved radiotracer for positron emission tomography (PET) myocardial perfusion imaging (MPI) with favorable physical properties and demonstrated superiority over single-photon emission computed tomography MPI in prior trials. However, no direct comparisons with the widely used rubidium-82 (Rb-82) tracer have been reported to date. CASE SUMMARY: We present the case of a 71-year-old man with coronary artery disease who underwent a clinically indicated Rb-82 PET MPI followed 2 weeks later by an F-18 flurpiridaz PET MPI for research purposes. DISCUSSION: This case highlights the potential advantages of F-18 flurpiridaz. Compared with Rb-82 PET, the F-18 flurpiridaz PET demonstrated superior image quality, more pronounced splenic switch-off, and higher stress myocardial blood flow and myocardial flow reserve. These differences may be attributed to the shorter positron range, higher myocardial extraction fraction, and near-linear relationship with myocardial blood flow of F-18 flurpiridaz. TAKE-HOME MESSAGES: F-18 flurpiridaz PET MPI demonstrated superior image quality compared with Rb-82 PET MPI. Splenic switch-off was more visually and quantitatively pronounced with F-18 flurpiridaz, potentially improving the ability to distinguish responders to regadenoson from nonresponders. Stress myocardial blood flow and myocardial flow reserve were higher with F-18 flurpiridaz, in part owing to its higher myocardial extraction fraction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.